Diaceutics PLC Results of Annual General Meeting (9077Z)
18 Maggio 2023 - 12:46PM
UK Regulatory
TIDMDXRX
RNS Number : 9077Z
Diaceutics PLC
18 May 2023
18 May 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Results of Annual General Meeting
Diaceutics PLC (AIM: DXRX), a leading technology and solutions
provider to the pharmaceutical industry, is pleased to announce
that all resolutions proposed at its Annual General Meeting held
earlier today, were duly passed.
The proxy votes received from shareholders in respect of each
resolution are set out below and are available on the Company's
website www.diaceutics.com
Resolution For (excluding Against Total Withheld
at Chair's discretion) votes cast
Number %* Number %* Number of
of votes of votes votes
------------------------------- --------------- --------- ---------- ------- ------------ -----------
Ordinary resolution
to receive and consider
the 2022 Financial
1 Statements 60,055,552 100.00% 0 0.00% 60,055,552 Nil
------------------------------- --------------- --------- ---------- ------- ------------ -----------
Ordinary resolution
to approve the directors'
2 remuneration report 51,885,466 89.43% 6,131,086 10.57% 60,055,552 2,039,000
------------------------------- --------------- --------- ---------- ------- ------------ -----------
Ordinary resolution
to re-elect Peter
3 Keeling as a director 59,406,925 98.92% 648,627 1.08% 60,055,552 Nil
------------------------------- --------------- --------- ---------- ------- ------------ -----------
Ordinary resolution
to re-elect Michael
4 Wort as a director 55,788,593 92.89% 4,266,959 7.11% 60,055,552 Nil
------------------------------- --------------- --------- ---------- ------- ------------ -----------
Ordinary resolution
to re-appoint Ernst
5 & Young as auditors 60,055,552 100.00% 0 0.00% 60,055,552 Nil
------------------------------- --------------- --------- ---------- ------- ------------ -----------
Ordinary resolution
to authorise the directors
to determine the remuneration
6 of the auditors 60,055,552 100.00% 0 0.00% 60,055,552 Nil
------------------------------- --------------- --------- ---------- ------- ------------ -----------
Ordinary resolution
to authorise the directors
7 to allot shares 60,055,552 100.00% 0 0.00% 60,055,552 Nil
------------------------------- --------------- --------- ---------- ------- ------------ -----------
Special resolution
to authorise the directors
to disapply pre-emption
8 rights 60,055,202 99.9% 350 0.01% 60,055,552 Nil
------------------------------- --------------- --------- ---------- ------- ------------ -----------
Special resolution
to authorise the directors
9 to purchase own shares 59,976,122 100.00% 0 0.00% 60,055,552 79,430
------------------------------- --------------- --------- ---------- ------- ------------ -----------
*Percentage of votes cast excludes withheld votes
Enquiries:
Diaceutics PLC
Peter Keeling, Chief Executive Officer Via Alma PR
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison, Nick Harland, Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde, Kieran Breheny, Matthew Young, diaceutics@almapr.co.uk
Kinvara Verdon
About Diaceutics
At Diaceutics we believe that every patient should get the
opportunity to receive the right test and the right therapy to
positively impact their disease outcome. We provide the world's
leading pharmaceutical and life science companies with solutions
and technology for the commercialisation of their precision
medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, utilising a global network of affiliate
laboratories to deliver multiple pipelines of real--world
healthcare data insights, advisory services and innovative platform
enabled solutions.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGGPURWAUPWGUR
(END) Dow Jones Newswires
May 18, 2023 06:46 ET (10:46 GMT)
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Mag 2023 a Mag 2024